{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:04:32Z","timestamp":1780452272956,"version":"3.54.1"},"reference-count":52,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Inhalant use disorder is a substance use disorder that involves the inhalation of volatile hydrocarbons (VHCs) to experience intoxication. Despite its prevalence and potential for adverse events, pharmacotherapy research for inhalant use disorder is limited. Acamprosate is a medication used for alcohol use disorder (AUD) that may provide benefit for inhalant use disorder. Acamprosate, alcohol, and inhalants all modulate glutamatergic and GABAergic pathways to produce their effects. Reported is a case of inhalant use disorder with comorbid AUD treated successfully with acamprosate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Report<\/jats:title>\n                    <jats:p>Patient A is a 39-year-old male consuming 16 cans of computer duster per day, having escalated use over the course of 2 weeks following a period of sobriety. He has been abstaining from alcohol with the help of disulfiram therapy. Following medical management, chronic inhalant use disorder pharmacotherapy was established with acamprosate 666 mg twice a day and later increased to 999 mg twice a day.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Similarities in effect may lead to the comorbid use pattern of inhalants and alcohol for our patient. As disulfiram did not address the inhalant use, acamprosate was chosen in hopes of reducing cravings and encouraging abstinence in the long term.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Inhalant use disorder represents an understudied substance use disorder, and acamprosate may be a promising medication to investigate for broader safety and efficacy. Patients with comorbid AUD may be an especially likely population to benefit from acamprosate therapy due to the possibility of dual benefit from the FDA-approved AUD indication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.9740\/mhc.2026.06.159","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T01:42:05Z","timestamp":1780364525000},"page":"159-162","source":"Crossref","is-referenced-by-count":0,"title":["Case report: Acamprosate for treatment of volatile hydrocarbon (VHC) inhalant use disorder with comorbid alcohol use disorder"],"prefix":"10.9740","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1679-4377","authenticated-orcid":true,"given":"Nariman","family":"Piri","sequence":"first","affiliation":[{"name":"(Corresponding author) Inpatient Psychiatric Pharmacist, Sutter Health Alta Bates Medical Center \u2013 Herrick Campus, Berkeley, California, npiri.mail@gmail.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1659-3221","authenticated-orcid":true,"given":"Wesley","family":"Campbell","sequence":"additional","affiliation":[{"name":"Inpatient Psychiatric Pharmacist, Raymond G. Murphy Medical Center of the New Mexico VA Health Care system, Albuquerque, New Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","reference":[{"key":"i2168-9709-16-3-159-b01","article-title":"NSDUH detailed tables","author":"Substance Abuse and Mental Health Services Administration","year":"(2023)","unstructured":"Substance Abuse and Mental Health Services Administration (2023). NSDUH detailed tables. https:\/\/www.samhsa.gov\/data\/report\/2023-nsduh-detailed-tables"},{"issue":"2","key":"i2168-9709-16-3-159-b02","series-title":"Perm J","first-page":"99","article-title":"The clinical assessment and treatment of inhalant abuse","volume":"27","author":"Radparvar","year":"2023","unstructured":"Radparvar S. The clinical assessment and treatment of inhalant abuse. Perm J. 2023;27(2):99-109. DOI: 10.7812\/TPP\/22.164"},{"issue":"13","key":"i2168-9709-16-3-159-b03","series-title":"Neuropsychopharmacology","first-page":"2555","article-title":"Volatile solvents as drugs of abuse: focus on the cortico-mesolimbic circuitry","volume":"38","author":"Beckley","year":"2013","unstructured":"Beckley JT,\nWoodward JJ. Volatile solvents as drugs of abuse: focus on the cortico-mesolimbic circuitry. Neuropsychopharmacology. 2013;38(13):2555-67. DOI: 10.1038\/npp.2013.206"},{"key":"i2168-9709-16-3-159-b04","series-title":"Neurosci Lett","first-page":"68","article-title":"Abuse potential and dopaminergic effect of alkyl nitrites","volume":"629","author":"Jeon","year":"2016","unstructured":"Jeon SY,\nKim YJ,\nKim YH,\nShin J,\nYun J,\nHan K, et al. Abuse potential and dopaminergic effect of alkyl nitrites. Neurosci Lett. 2016;629:68-72. DOI: 10.1016\/j.neulet.2016.06.057"},{"issue":"4","key":"i2168-9709-16-3-159-b05","series-title":"Anesthesiology","first-page":"707","article-title":"Biologic effects of nitrous oxide: a mechanistic and toxicologic review","volume":"109","author":"Sanders","year":"2008","unstructured":"Sanders R,\nWeimann J,\nMaze M,\nWarner D,\nWarner MA. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. Anesthesiology 2008;109(4):707-22. DOI: 10.1097\/ALN.0b013e3181870a17"},{"issue":"11","key":"i2168-9709-16-3-159-b06","series-title":"Cureus","first-page":"e19897","article-title":"Acute inhalant-induced atrial fibrillation with severe hypocalcemia: a case report and review of the pathophysiology","volume":"13","author":"George","year":"2021","unstructured":"George N,\nChin B,\nNeeki AS,\nDong F,\nNeeki MM. Acute inhalant-induced atrial fibrillation with severe hypocalcemia: a case report and review of the pathophysiology. Cureus. 2021;13(11):e19897. DOI: 10.7759\/cureus.19897"},{"issue":"6","key":"i2168-9709-16-3-159-b07","series-title":"Cureus","first-page":"e8402","article-title":"Air duster inhalant abuse causing non-st elevation myocardial infarction","volume":"12","author":"Cao","year":"2020","unstructured":"Cao SA,\nRay M,\nKlebanov N. Air duster inhalant abuse causing non-st elevation myocardial infarction. Cureus. 2020;12(6):e8402. DOI: 10.7759\/cureus.8402"},{"key":"i2168-9709-16-3-159-b08","series-title":"BMC Emerg Med","article-title":"Acute toluene intoxication\u2013clinical presentation, management and prognosis: a prospective observational study","volume":"15;19","author":"Camara-Lemarroy","year":"2015","unstructured":"Camara-Lemarroy CR,\nRodr\u00edguez-Guti\u00e9rrez R,\nMonreal-Robles R,\nGonz\u00e1lez-Gonz\u00e1lez JG. Acute toluene intoxication\u2013clinical presentation, management and prognosis: a prospective observational study. BMC Emerg Med. 2015;15;19. DOI: 10.1186\/s12873-015-0039-0"},{"issue":"2","key":"i2168-9709-16-3-159-b09","series-title":"Perm J","first-page":"99","article-title":"The clinical assessment and treatment of inhalant abuse","volume":"27","author":"Radparvar","year":"2023","unstructured":"Radparvar S. The clinical assessment and treatment of inhalant abuse. Perm J. 2023;27(2):99-109. DOI: 10.7812\/TPP\/22.164"},{"issue":"1","key":"i2168-9709-16-3-159-b10","series-title":"Toxicol Commun","article-title":"Thermal injury after \u201chuffing\u201d compressed air duster: a case report","volume":"8","author":"Katz","year":"2024","unstructured":"Katz J,\nDorey A. Thermal injury after \u201chuffing\u201d compressed air duster: a case report. Toxicol Commun. 2024;8(1). DOI: 10.1080\/24734306.2024.2380932"},{"issue":"7","key":"i2168-9709-16-3-159-b11","series-title":"Am J Emerg Med","first-page":"704","article-title":"Patterns and correlates of drug-related ED visits: results from a national survey","volume":"29","author":"Perron","year":"2011","unstructured":"Perron BE,\nBohnert AS,\nMonsell SE,\nVaughn MG,\nEpperson M,\nHoward MO. Patterns and correlates of drug-related ED visits: results from a national survey. Am J Emerg Med. 2011;29(7):704-10. DOI: 10.1016\/j.ajem.2010.01.044"},{"issue":"6","key":"i2168-9709-16-3-159-b12","series-title":"Addiction","first-page":"1107","article-title":"A prospective study of neurocognitive changes 15 years after chronic inhalant abuse","volume":"108","author":"Cairney","year":"2013","unstructured":"Cairney S,\nO\u2019 Connor N,\nDingwall KM,\nMaruff P,\nShafiq-Antonacci R,\nCurrie J, et al. A prospective study of neurocognitive changes 15 years after chronic inhalant abuse. Addiction. 2013;108(6):1107-14. DOI: 10.1111\/add.12124"},{"key":"i2168-9709-16-3-159-b13","series-title":"Addict Neurosci","first-page":"100059","article-title":"The effects of the inhalant toluene on cognitive function and behavioral flexibility: a review of recent findings","volume":"5","author":"Woodward","year":"2023","unstructured":"Woodward JJ,\nBraunscheidel KM. The effects of the inhalant toluene on cognitive function and behavioral flexibility: a review of recent findings. Addict Neurosci. 2023;5:100059. DOI: 10.1016\/j.addicn.2022.100059"},{"key":"i2168-9709-16-3-159-b14","series-title":"N Engl J Med","first-page":"872","article-title":"BENZENE AND LEUKEMIA","volume":"271","author":"VIGLIANI","year":"1964","unstructured":"VIGLIANI EC,\nSAITA G. BENZENE AND LEUKEMIA. N Engl J Med. 1964;271:872-876. DOI: 10.1056\/NEJM196410222711703"},{"issue":"1","key":"i2168-9709-16-3-159-b15","series-title":"Am J Addict","first-page":"69","article-title":"Treating inhalant abuse with buspirone","volume":"16","author":"Niederhofer","year":"2007","unstructured":"Niederhofer H. Treating inhalant abuse with buspirone. Am J Addict. 2007 Jan-Feb;16(1):69. DOI: 10.1080\/10550490601080126. PMID: 17364426."},{"issue":"6","key":"i2168-9709-16-3-159-b16","series-title":"Psychiatr Serv","first-page":"812","article-title":"Treatment of inhalant-induced psychotic disorder with carbamazepine versus haloperidol","volume":"49","author":"Hernandez-Avila","year":"1998","unstructured":"Hernandez-Avila CA,\nOrtega-Soto HA,\nJasso A,\nHasfura-Buenaga CA,\nKranzler HR. Treatment of inhalant-induced psychotic disorder with carbamazepine versus haloperidol. Psychiatr Serv. 1998 Jun;49(6):812-5. DOI: 10.1176\/ps.49.6.812. PMID: 9634163."},{"issue":"3","key":"i2168-9709-16-3-159-b17","series-title":"Prog Neuropsychopharmacol Biol Psychiatry","first-page":"769","article-title":"Treatment of inhalant dependence with lamotrigine","volume":"31","author":"Shen","year":"2007","unstructured":"Shen YC. Treatment of inhalant dependence with lamotrigine. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(3):769-71. DOI: 10.1016\/j.pnpbp.2006.12.016"},{"issue":"9","key":"i2168-9709-16-3-159-b18","series-title":"J Clin Psychiatry","first-page":"620","article-title":"Treatment of inhalant abuse with risperidone","volume":"60","author":"Misra","year":"1999","unstructured":"Misra LK,\nKofoed L,\nFuller W. Treatment of inhalant abuse with risperidone. J Clin Psychiatry. 1999;60(9):620. DOI: 10.4088\/jcp.v60n0915"},{"issue":"1","key":"i2168-9709-16-3-159-b19","series-title":"Addict Sci Clin Pract","first-page":"18","article-title":"Inhalant use and inhalant use disorders in the United States","volume":"6","author":"Howard","year":"2011","unstructured":"Howard MO,\nBowen SE,\nGarland EL,\nPerron BE,\nVaughn MG. Inhalant use and inhalant use disorders in the United States. Addict Sci Clin Pract. 2011;6(1):18-31. PMID: 22003419"},{"issue":"3","key":"i2168-9709-16-3-159-b20","series-title":"Subst Use Addctn J","first-page":"718","article-title":"Case report: dust remover inhalant use disorder in an individual in early remission from alcohol use disorder treated with naltrexone","volume":"46","author":"Reddy","year":"2025","unstructured":"Reddy IA,\nBallester J. Case report: dust remover inhalant use disorder in an individual in early remission from alcohol use disorder treated with naltrexone. Subst Use Addctn J. 2025;46(3):718-21. DOI: 10.1177\/29767342241297436"},{"issue":"2","key":"i2168-9709-16-3-159-b21","series-title":"Br J Clin Pharmacol","first-page":"315","article-title":"The clinical pharmacology of acamprosate","volume":"77","author":"Kalk","year":"2014","unstructured":"Kalk NJ,\nLingford-Hughes AR. The clinical pharmacology of acamprosate. Br J Clin Pharmacol. 2014;77(2):315-23. DOI: 10.1111\/bcp.12070"},{"issue":"2","key":"i2168-9709-16-3-159-b22","series-title":"Br J Pharmacol","first-page":"316","article-title":"Inhalant abuse among adolescents: neurobiological considerations","volume":"154","author":"Lubman","year":"2008","unstructured":"Lubman DI,\nY\u00fccel M,\nLawrence AJ. Inhalant abuse among adolescents: neurobiological considerations. Br J Pharmacol. 2008;154(2):316-26. DOI: 10.1038\/bjp.2008.76"},{"issue":"9","key":"i2168-9709-16-3-159-b23","series-title":"Cochrane Database Syst Rev","first-page":"CD004332","article-title":"Acamprosate for alcohol dependence","volume":"2010","author":"R\u00f6sner","year":"2010","unstructured":"R\u00f6sner S,\nHackl-Herrwerth A,\nLeucht S,\nLehert P,\nVecchi S,\nSoyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;2010(9):CD004332. DOI: 10.1002\/14651858.CD004332.pub2"},{"issue":"2","key":"i2168-9709-16-3-159-b24","series-title":"J Clin Psychiatry","first-page":"181","article-title":"Efficacy of acamprosate for the treatment of alcohol dependence long after recovery from withdrawal syndrome: a randomized, double-blind, placebo-controlled study conducted in Japan (Sunrise Study)","volume":"76","author":"Higuchi","year":"2015","unstructured":"Higuchi S; Japanese Acamprosate Study Group. Efficacy of acamprosate for the treatment of alcohol dependence long after recovery from withdrawal syndrome: a randomized, double-blind, placebo-controlled study conducted in Japan (Sunrise Study). J Clin Psychiatry. 2015;76(2):181-8. DOI: 10.4088\/JCP.13m08940"},{"issue":"6","key":"i2168-9709-16-3-159-b25","series-title":"Addict Biol","first-page":"1528","article-title":"Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone","volume":"22","author":"Roos","year":"2017","unstructured":"Roos CR,\nMann K,\nWitkiewitz K. Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone. Addict Biol. 2017;22(6):1528-39. DOI: 10.1111\/adb.12427"},{"issue":"2","key":"i2168-9709-16-3-159-b26","series-title":"Ment Health Clin","first-page":"56","article-title":"Review of acamprosate pharmacokinetics and dosing strategies","volume":"15","author":"Steil","year":"2025","unstructured":"Steil L,\nTerasaki D,\nReiss R,\nDeaney M. Review of acamprosate pharmacokinetics and dosing strategies. Ment Health Clin. 2025;15(2):56-61. DOI: 10.9740\/mhc.2025.04.056"},{"key":"i2168-9709-16-3-159-b01","article-title":"NSDUH detailed tables","author":"Substance Abuse and Mental Health Services Administration","year":"(2023)","unstructured":"Substance Abuse and Mental Health Services Administration (2023). NSDUH detailed tables. https:\/\/www.samhsa.gov\/data\/report\/2023-nsduh-detailed-tables"},{"issue":"2","key":"i2168-9709-16-3-159-b02","series-title":"Perm J","first-page":"99","article-title":"The clinical assessment and treatment of inhalant abuse","volume":"27","author":"Radparvar","year":"2023","unstructured":"Radparvar S. The clinical assessment and treatment of inhalant abuse. Perm J. 2023;27(2):99-109. DOI: 10.7812\/TPP\/22.164"},{"issue":"13","key":"i2168-9709-16-3-159-b03","series-title":"Neuropsychopharmacology","first-page":"2555","article-title":"Volatile solvents as drugs of abuse: focus on the cortico-mesolimbic circuitry","volume":"38","author":"Beckley","year":"2013","unstructured":"Beckley JT,\nWoodward JJ. Volatile solvents as drugs of abuse: focus on the cortico-mesolimbic circuitry. Neuropsychopharmacology. 2013;38(13):2555-67. DOI: 10.1038\/npp.2013.206"},{"key":"i2168-9709-16-3-159-b04","series-title":"Neurosci Lett","first-page":"68","article-title":"Abuse potential and dopaminergic effect of alkyl nitrites","volume":"629","author":"Jeon","year":"2016","unstructured":"Jeon SY,\nKim YJ,\nKim YH,\nShin J,\nYun J,\nHan K, et al. Abuse potential and dopaminergic effect of alkyl nitrites. Neurosci Lett. 2016;629:68-72. DOI: 10.1016\/j.neulet.2016.06.057"},{"issue":"4","key":"i2168-9709-16-3-159-b05","series-title":"Anesthesiology","first-page":"707","article-title":"Biologic effects of nitrous oxide: a mechanistic and toxicologic review","volume":"109","author":"Sanders","year":"2008","unstructured":"Sanders R,\nWeimann J,\nMaze M,\nWarner D,\nWarner MA. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. Anesthesiology 2008;109(4):707-22. DOI: 10.1097\/ALN.0b013e3181870a17"},{"issue":"11","key":"i2168-9709-16-3-159-b06","series-title":"Cureus","first-page":"e19897","article-title":"Acute inhalant-induced atrial fibrillation with severe hypocalcemia: a case report and review of the pathophysiology","volume":"13","author":"George","year":"2021","unstructured":"George N,\nChin B,\nNeeki AS,\nDong F,\nNeeki MM. Acute inhalant-induced atrial fibrillation with severe hypocalcemia: a case report and review of the pathophysiology. Cureus. 2021;13(11):e19897. DOI: 10.7759\/cureus.19897"},{"issue":"6","key":"i2168-9709-16-3-159-b07","series-title":"Cureus","first-page":"e8402","article-title":"Air duster inhalant abuse causing non-st elevation myocardial infarction","volume":"12","author":"Cao","year":"2020","unstructured":"Cao SA,\nRay M,\nKlebanov N. Air duster inhalant abuse causing non-st elevation myocardial infarction. Cureus. 2020;12(6):e8402. DOI: 10.7759\/cureus.8402"},{"key":"i2168-9709-16-3-159-b08","series-title":"BMC Emerg Med","article-title":"Acute toluene intoxication\u2013clinical presentation, management and prognosis: a prospective observational study","volume":"15;19","author":"Camara-Lemarroy","year":"2015","unstructured":"Camara-Lemarroy CR,\nRodr\u00edguez-Guti\u00e9rrez R,\nMonreal-Robles R,\nGonz\u00e1lez-Gonz\u00e1lez JG. Acute toluene intoxication\u2013clinical presentation, management and prognosis: a prospective observational study. BMC Emerg Med. 2015;15;19. DOI: 10.1186\/s12873-015-0039-0"},{"issue":"2","key":"i2168-9709-16-3-159-b09","series-title":"Perm J","first-page":"99","article-title":"The clinical assessment and treatment of inhalant abuse","volume":"27","author":"Radparvar","year":"2023","unstructured":"Radparvar S. The clinical assessment and treatment of inhalant abuse. Perm J. 2023;27(2):99-109. DOI: 10.7812\/TPP\/22.164"},{"issue":"1","key":"i2168-9709-16-3-159-b10","series-title":"Toxicol Commun","article-title":"Thermal injury after \u201chuffing\u201d compressed air duster: a case report","volume":"8","author":"Katz","year":"2024","unstructured":"Katz J,\nDorey A. Thermal injury after \u201chuffing\u201d compressed air duster: a case report. Toxicol Commun. 2024;8(1). DOI: 10.1080\/24734306.2024.2380932"},{"issue":"7","key":"i2168-9709-16-3-159-b11","series-title":"Am J Emerg Med","first-page":"704","article-title":"Patterns and correlates of drug-related ED visits: results from a national survey","volume":"29","author":"Perron","year":"2011","unstructured":"Perron BE,\nBohnert AS,\nMonsell SE,\nVaughn MG,\nEpperson M,\nHoward MO. Patterns and correlates of drug-related ED visits: results from a national survey. Am J Emerg Med. 2011;29(7):704-10. DOI: 10.1016\/j.ajem.2010.01.044"},{"issue":"6","key":"i2168-9709-16-3-159-b12","series-title":"Addiction","first-page":"1107","article-title":"A prospective study of neurocognitive changes 15 years after chronic inhalant abuse","volume":"108","author":"Cairney","year":"2013","unstructured":"Cairney S,\nO\u2019 Connor N,\nDingwall KM,\nMaruff P,\nShafiq-Antonacci R,\nCurrie J, et al. A prospective study of neurocognitive changes 15 years after chronic inhalant abuse. Addiction. 2013;108(6):1107-14. DOI: 10.1111\/add.12124"},{"key":"i2168-9709-16-3-159-b13","series-title":"Addict Neurosci","first-page":"100059","article-title":"The effects of the inhalant toluene on cognitive function and behavioral flexibility: a review of recent findings","volume":"5","author":"Woodward","year":"2023","unstructured":"Woodward JJ,\nBraunscheidel KM. The effects of the inhalant toluene on cognitive function and behavioral flexibility: a review of recent findings. Addict Neurosci. 2023;5:100059. DOI: 10.1016\/j.addicn.2022.100059"},{"key":"i2168-9709-16-3-159-b14","series-title":"N Engl J Med","first-page":"872","article-title":"BENZENE AND LEUKEMIA","volume":"271","author":"VIGLIANI","year":"1964","unstructured":"VIGLIANI EC,\nSAITA G. BENZENE AND LEUKEMIA. N Engl J Med. 1964;271:872-876. DOI: 10.1056\/NEJM196410222711703"},{"issue":"1","key":"i2168-9709-16-3-159-b15","series-title":"Am J Addict","first-page":"69","article-title":"Treating inhalant abuse with buspirone","volume":"16","author":"Niederhofer","year":"2007","unstructured":"Niederhofer H. Treating inhalant abuse with buspirone. Am J Addict. 2007 Jan-Feb;16(1):69. DOI: 10.1080\/10550490601080126. PMID: 17364426."},{"issue":"6","key":"i2168-9709-16-3-159-b16","series-title":"Psychiatr Serv","first-page":"812","article-title":"Treatment of inhalant-induced psychotic disorder with carbamazepine versus haloperidol","volume":"49","author":"Hernandez-Avila","year":"1998","unstructured":"Hernandez-Avila CA,\nOrtega-Soto HA,\nJasso A,\nHasfura-Buenaga CA,\nKranzler HR. Treatment of inhalant-induced psychotic disorder with carbamazepine versus haloperidol. Psychiatr Serv. 1998 Jun;49(6):812-5. DOI: 10.1176\/ps.49.6.812. PMID: 9634163."},{"issue":"3","key":"i2168-9709-16-3-159-b17","series-title":"Prog Neuropsychopharmacol Biol Psychiatry","first-page":"769","article-title":"Treatment of inhalant dependence with lamotrigine","volume":"31","author":"Shen","year":"2007","unstructured":"Shen YC. Treatment of inhalant dependence with lamotrigine. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(3):769-71. DOI: 10.1016\/j.pnpbp.2006.12.016"},{"issue":"9","key":"i2168-9709-16-3-159-b18","series-title":"J Clin Psychiatry","first-page":"620","article-title":"Treatment of inhalant abuse with risperidone","volume":"60","author":"Misra","year":"1999","unstructured":"Misra LK,\nKofoed L,\nFuller W. Treatment of inhalant abuse with risperidone. J Clin Psychiatry. 1999;60(9):620. DOI: 10.4088\/jcp.v60n0915"},{"issue":"1","key":"i2168-9709-16-3-159-b19","series-title":"Addict Sci Clin Pract","first-page":"18","article-title":"Inhalant use and inhalant use disorders in the United States","volume":"6","author":"Howard","year":"2011","unstructured":"Howard MO,\nBowen SE,\nGarland EL,\nPerron BE,\nVaughn MG. Inhalant use and inhalant use disorders in the United States. Addict Sci Clin Pract. 2011;6(1):18-31. PMID: 22003419"},{"issue":"3","key":"i2168-9709-16-3-159-b20","series-title":"Subst Use Addctn J","first-page":"718","article-title":"Case report: dust remover inhalant use disorder in an individual in early remission from alcohol use disorder treated with naltrexone","volume":"46","author":"Reddy","year":"2025","unstructured":"Reddy IA,\nBallester J. Case report: dust remover inhalant use disorder in an individual in early remission from alcohol use disorder treated with naltrexone. Subst Use Addctn J. 2025;46(3):718-21. DOI: 10.1177\/29767342241297436"},{"issue":"2","key":"i2168-9709-16-3-159-b21","series-title":"Br J Clin Pharmacol","first-page":"315","article-title":"The clinical pharmacology of acamprosate","volume":"77","author":"Kalk","year":"2014","unstructured":"Kalk NJ,\nLingford-Hughes AR. The clinical pharmacology of acamprosate. Br J Clin Pharmacol. 2014;77(2):315-23. DOI: 10.1111\/bcp.12070"},{"issue":"2","key":"i2168-9709-16-3-159-b22","series-title":"Br J Pharmacol","first-page":"316","article-title":"Inhalant abuse among adolescents: neurobiological considerations","volume":"154","author":"Lubman","year":"2008","unstructured":"Lubman DI,\nY\u00fccel M,\nLawrence AJ. Inhalant abuse among adolescents: neurobiological considerations. Br J Pharmacol. 2008;154(2):316-26. DOI: 10.1038\/bjp.2008.76"},{"issue":"9","key":"i2168-9709-16-3-159-b23","series-title":"Cochrane Database Syst Rev","first-page":"CD004332","article-title":"Acamprosate for alcohol dependence","volume":"2010","author":"R\u00f6sner","year":"2010","unstructured":"R\u00f6sner S,\nHackl-Herrwerth A,\nLeucht S,\nLehert P,\nVecchi S,\nSoyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;2010(9):CD004332. DOI: 10.1002\/14651858.CD004332.pub2"},{"issue":"2","key":"i2168-9709-16-3-159-b24","series-title":"J Clin Psychiatry","first-page":"181","article-title":"Efficacy of acamprosate for the treatment of alcohol dependence long after recovery from withdrawal syndrome: a randomized, double-blind, placebo-controlled study conducted in Japan (Sunrise Study)","volume":"76","author":"Higuchi","year":"2015","unstructured":"Higuchi S; Japanese Acamprosate Study Group. Efficacy of acamprosate for the treatment of alcohol dependence long after recovery from withdrawal syndrome: a randomized, double-blind, placebo-controlled study conducted in Japan (Sunrise Study). J Clin Psychiatry. 2015;76(2):181-8. DOI: 10.4088\/JCP.13m08940"},{"issue":"6","key":"i2168-9709-16-3-159-b25","series-title":"Addict Biol","first-page":"1528","article-title":"Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone","volume":"22","author":"Roos","year":"2017","unstructured":"Roos CR,\nMann K,\nWitkiewitz K. Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone. Addict Biol. 2017;22(6):1528-39. DOI: 10.1111\/adb.12427"},{"issue":"2","key":"i2168-9709-16-3-159-b26","series-title":"Ment Health Clin","first-page":"56","article-title":"Review of acamprosate pharmacokinetics and dosing strategies","volume":"15","author":"Steil","year":"2025","unstructured":"Steil L,\nTerasaki D,\nReiss R,\nDeaney M. Review of acamprosate pharmacokinetics and dosing strategies. Ment Health Clin. 2025;15(2):56-61. DOI: 10.9740\/mhc.2025.04.056"}],"container-title":["Mental Health Clinician"],"original-title":[],"link":[{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/16\/3\/article-p159.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/16\/3\/article-p159.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/16\/3\/article-p159.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:31:16Z","timestamp":1780450276000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/16\/3\/article-p159.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":52,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.9740\/mhc.2026.06.159","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}